Abstract:

HIV continues to be a major global public health issue, having claimed 36.3 million [27.2–47.8 million] lives so far (WHO, 2021). Sub-Sahara Africa remains the far worst affected region, with 20.6 million [16.8 million– 24.4 million] people living with HIV at the end of 2010, compared to 24.4 (22.5-27.3 million) in 2020. Complementary and alternative therapy (CAM) has been used to treat HIV patients by clinicians in conventional health services in combination with highly active antiretroviral therapy (HAART). To determine efficacy of Babao relief capsule when used as an adjuvant to standard HAART in antiretroviral naïve HIV patients. The product is a biological Chinese medicinal preparation, made of herbs. Ingredients include ginseng, beer antler, musk, bezoar, fleeceflower, Chinese angelica, lyceum, pericarpium citri reticulatae, safflower and ophiopogn japonicus. Open Label Phase 1 bridging Clinical trial to study the efficacy of Babao relief capsule when used in combination standard HAART in antiretroviral naïve HIV patients. A total of one hundred and ninety-six (196) adult patients attending the HIV clinic were randomly selected. The interventional group was on Babao relief capsule and HAART while the control group was on HAART only. The study shows general efficacy of the standard HAART drugs. However, the interventional arm showed a significant increase in the CD4 cell count, showing that BRC had booster effects in the efficacy of HAART.

Keywords: HIV, Complementary and alternative therapy, Babao relief capsule, standard highly active antiretroviral therapy.

References:

[1] World Health Organization, UNAIDS (2021). Retried from http://www.unaids.org.

[2] Ministry of Health (1999), “HIV/AIDS in Zambia: Background, Projections, Impact, Interventions.

[3] Poverty Analysis Zambia (2018). Retrieved from https://cdn.sida.se/app/uploads/2021/08/24151354/Multidimensional-Poverty-Analysis-Zambia-2018.pdf.

[4] Ni, H., Simile, C., & Hardy, A. M. (2002). Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Medical Care, 40, 353-358.

[5] Wiwanitkit, V. (2003). The use of CAM by HIV-positive patients in Thailand.Complementary Therapies in Medicine, 11, 39-41.

[6] Liu JP, Manheimer E, Yang M. (2005). Herb-al medicines for treating HIV infection and AIDS. Cochrane Database of Systematic Reviews;(3): Art. No.: CD003937. DOI: 10.1002/14651858.CD003937.pub2.

[7] Muller A, Kanfer I. (2011) Potential pharmacokinetic interactions between antiretrovirals and medicinal plants used as complementary and African traditional medicines. Biopharmaceutics and Drug Disposition;32(8):458-70.

[8] Mills, E., Montori, V., Perri, D., Phillips, E., & Koren, G. (2005). Natural health product-HIV drug interactions: a systematic review. International Journal of STD & AIDS, 16, 181-186.

[9] Felise B. Milan, Julia H. Arnsten, Robert S. Klein, Ellie E. Schoenbaum, Galina Moskaleva, Donna Buono, and Mayris P. Webber. (2010). Use of Complementary and Alternative Medicine in Inner-City Persons with or at Risk for HIV Infection. Retrieved from https://doi.org/10.1089/apc.2007.0159.

[10] Moffett H, Sanders P, and Sinclair T, Ergil K (1994): Using acupuncture and herbs for the treatment of HIV infection. AIDS Patient care; 8(4): 194-9.

[11] Ozsoy M, Ernst E (1990): How effective are complimentary therapies for HIV and AIDS? A systematic review. Int J STD AIDS; 10(10): 629-35.

[12] Shlay J., Chaloner. K, Mitchell. B. (1998). Acupuncture and Amitriptyline for Pain Due to HIV-Related Peripheral Neuropathy. A Randomized Controlled Trial. Retrieved from https://jamanetwork.com/journals/jama/article-abstract/188146.

[13] Smith M O (1988): AIDS: results of Chinese treatment show frequent symptom relief and some apparent long-term remissions. AM J Acupunct; 16(2): 20

[14] Su C (1991) (AIDS Trial Treatment Group, China Academy of TCM): Trial treatment of AIDS by TCM – A clinical report of 30 cases. J Chin Med (37): 17-20.

[15] Wiwanitkt, V. (2003). The use of CAM by HIV-Positive patients in Thailand. Complementary therapies in Medicine, 11, 39-41.

[16] Lohse. H Hansen. A, Pedersen. G, Kronborg. G, Gerstoft. J, Sørensen. T, Vaeth. M, Obel. N. (2007). Survival of persons with and without HIV infection in Denmark, 1995-2005. DOI: 10.7326/0003-4819-146-2-200701160-00003.

[17] WHO (2019). Dolutegravir (DTG) and the fixed dose combination of tenofovir/lamivudine/dolutegravir (TLD). Briefing Note.

[18] Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC (2009): Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. Jan;54(1):254-8. doi: 10.1128/AAC.00842-09.

[19] Katlama C, Murphy R (2012): Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs. 2012 Apr;21(4):523-30. doi: 10.1517/13543784.2012.661713.

[20] Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P (2011): Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72. doi: 10.1124/mol.111.073189.

[21] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY- NC-SA 3.0 IGO World Health Organization.